© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 19, 1458-1464,
October 3, 2001
© 2001 Oxford University Press
Prostasin, a Potential Serum Marker for Ovarian Cancer: Identification Through Microarray Technology
Affiliations of authors: S. C. Mok, G. K. Yiu, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; J. Chao, Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston; S. Skates, Gillette Center for Women's Cancer, Dana-Farber Cancer Institute, and Biostatistics Center, Massachusetts General Hospital, Boston; K. Wong, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston; M. G. Muto, R. S. Berkowitz, D. W. Cramer, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, and Gillette Center for Women's Cancer, Dana-Farber Cancer Institute.
Correspondence to: Samuel C. Mok, Ph.D., Laboratory of Gynecologic Oncology, Brigham and Women's Hospital, 221 Longwood Ave., BLI 449, Boston, MA 02115 (e-mail: scmok{at}rics.bwh.harvard.edu).
Background: Screening biomarkers for ovarian cancer are needed because of its late stage at diagnosis and poor survival. We used microarray technology to identify overexpressed genes for secretory proteins as potential serum biomarkers and selected prostasin, a serine protease normally secreted by the prostate gland, for further study. Methods: RNA was isolated and pooled from three ovarian cancer cell lines and from three normal human ovarian surface epithelial (HOSE) cell lines. Complementary DNA generated from these pools was hybridized to a microarray slide, and genes overexpressed in the cancer cells were identified. Real-time quantitative polymerase chain reaction was used to examine prostasin gene expression in ovarian cancer and HOSE cell lines. Anti-prostasin antibodies were used to examine prostasin expression and to measure serum prostasin by an enzyme-linked immunosorbent assay in 64 case patients with ovarian cancer and in 137 control subjects. Previously determined levels of CA 125, an ovarian cancer marker, were available from about 70% of all subjects. All statistical tests were two-sided. Results: Prostasin was detected by immunostaining more strongly in cancerous ovarian epithelial cells and stroma than in normal ovarian tissue. The mean level of serum prostasin was 13.7 µg/mL (95% confidence interval [CI] = 10.5 to 16.9 µg/mL) in 64 case patients with ovarian cancer and 7.5 µg/mL (95% CI = 6.6 to 8.3 µg/mL) in 137 control subjects (P<.001, after adjustment for the subject's age, year of collection, and specimen quality). In 14 of 16 case patients with both preoperative and postoperative serum samples, postoperative prostasin levels were statistically significantly lower than preoperative levels (P = .004). In 37 case patients with nonmucinous ovarian cancer and in 100 control subjects for whom levels of CA 125 and prostasin were available, the combination of markers gave a sensitivity of 92% (95% CI = 78.1% to 98.3%) and a specificity of 94% (95% CI = 87.4% to 97.7%) for detecting ovarian cancer. Conclusions: Prostasin is overexpressed in epithelial ovarian cancer and should be investigated further as a screening or tumor marker, alone and in combination with CA 125.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers Clin. Chem., December 1, 2008; 54(12): e11 - e79. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Cui, Q. Liu, D. Puett, and Y. Xu Computational prediction of human proteins that can be secreted into the bloodstream Bioinformatics, October 15, 2008; 24(20): 2370 - 2375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Trope and J. Kaern Adjuvant Chemotherapy for Early-Stage Ovarian Cancer: Review of the Literature J. Clin. Oncol., July 10, 2007; 25(20): 2909 - 2920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Meinhold-Heerlein, D. Bauerschlag, Y. Zhou, L. M. Sapinoso, K. Ching, H. Frierson Jr., K. Brautigam, J. Sehouli, E. Stickeler, D. Konsgen, et al. An Integrated Clinical-Genomics Approach Identifies a Candidate Multi-Analyte Blood Test for Serous Ovarian Carcinoma Clin. Cancer Res., January 15, 2007; 13(2): 458 - 466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Netzel-Arnett, B. M. Currie, R. Szabo, C.-Y. Lin, L.-M. Chen, K. X. Chai, T. M. Antalis, T. H. Bugge, and K. List Evidence for a Matriptase-Prostasin Proteolytic Cascade Regulating Terminal Epidermal Differentiation J. Biol. Chem., November 3, 2006; 281(44): 32941 - 32945. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. F. Chambers and B. C. Vanderhyden Ovarian Cancer Biomarkers in Urine Clin. Cancer Res., January 15, 2006; 12(2): 323 - 327. [Full Text] [PDF]
|
|
|
|
|
|
B. Fan, T. D. Wu, W. Li, and D. Kirchhofer Identification of Hepatocyte Growth Factor Activator Inhibitor-1B as a Potential Physiological Inhibitor of Prostasin J. Biol. Chem., October 14, 2005; 280(41): 34513 - 34520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Tebben, K. R. Kalli, W. A. Cliby, L. C. Hartmann, J. P. Grande, R. J. Singh, and R. Kumar Elevated Fibroblast Growth Factor 23 in Women With Malignant Ovarian Tumors Mayo Clin. Proc., June 1, 2005; 80(6): 745 - 751. [Abstract] [PDF]
|
|
|
|
|
|
J. J. Liu, G. Cutler, W. Li, Z. Pan, S. Peng, T. Hoey, L. Chen, and X. B. Ling Multiclass cancer classification and biomarker discovery using GA-based algorithms Bioinformatics, June 1, 2005; 21(11): 2691 - 2697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Narod and K. Offit Prevention and Management of Hereditary Breast Cancer J. Clin. Oncol., March 10, 2005; 23(8): 1656 - 1663. [Full Text] [PDF]
|
|
|
|
|
|
H. Matsuzaki, H. Kobayashi, T. Yagyu, K. Wakahara, T. Kondo, N. Kurita, H. Sekino, K. Inagaki, M. Suzuki, N. Kanayama, et al. Plasma Bikunin As a Favorable Prognostic Factor in Ovarian Cancer J. Clin. Oncol., March 1, 2005; 23(7): 1463 - 1472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Michael and M.M. Doherty Tumoral Drug Metabolism: Overview and Its Implications for Cancer Therapy J. Clin. Oncol., January 1, 2005; 23(1): 205 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Zhang, R. C. Bast Jr., Y. Yu, J. Li, L. J. Sokoll, A. J. Rai, J. M. Rosenzweig, B. Cameron, Y. Y. Wang, X.-Y. Meng, et al. Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer Cancer Res., August 15, 2004; 64(16): 5882 - 5890. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hibbs, K. M. Skubitz, S. E. Pambuccian, R. C. Casey, K. M. Burleson, T. R. Oegema Jr, J. J. Thiele, S. M. Grindle, R. L. Bliss, and A. P.N. Skubitz Differential Gene Expression in Ovarian Carcinoma: Identification of Potential Biomarkers Am. J. Pathol., August 1, 2004; 165(2): 397 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Sutphen, Y. Xu, G. D. Wilbanks, J. Fiorica, E. C. Grendys Jr., J. P. LaPolla, H. Arango, M. S. Hoffman, M. Martino, K. Wakeley, et al. Lysophospholipids Are Potential Biomarkers of Ovarian Cancer Cancer Epidemiol. Biomarkers Prev., July 1, 2004; 13(7): 1185 - 1191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. O. Schorge, R. D. Drake, H. Lee, S. J. Skates, R. Rajanbabu, D. S. Miller, J.-H. Kim, D. W. Cramer, R. S. Berkowitz, and S. C. Mok Osteopontin as an Adjunct to CA125 in Detecting Recurrent Ovarian Cancer Clin. Cancer Res., May 15, 2004; 10(10): 3474 - 3478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. J. Jacobs and U. Menon Progress and Challenges in Screening for Early Detection of Ovarian Cancer Mol. Cell. Proteomics, April 1, 2004; 3(4): 355 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-H. Kim, D. Herlyn, K.-k. Wong, D.-C. Park, J. O. Schorge, K. H. Lu, S. J. Skates, D. W. Cramer, R. S. Berkowitz, and S. C. Mok Identification of Epithelial Cell Adhesion Molecule Autoantibody in Patients with Ovarian Cancer Clin. Cancer Res., October 15, 2003; 9(13): 4782 - 4791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Kozak, M. W. Amneus, S. M. Pusey, F. Su, M. N. Luong, S. A. Luong, S. T. Reddy, and R. Farias-Eisner Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis PNAS, October 14, 2003; 100(21): 12343 - 12348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Yousef, A. Scorilas, D. Katsaros, S. Fracchioli, L. Iskander, C. Borgono, I. A. Rigault de la Longrais, M. Puopolo, M. Massobrio, and E. P. Diamandis Prognostic Value of the Human Kallikrein Gene 15 Expression in Ovarian Cancer J. Clin. Oncol., August 15, 2003; 21(16): 3119 - 3126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Ye, D. W. Cramer, S. J. Skates, S. P. Gygi, V. Pratomo, L. Fu, N. K. Horick, L. J. Licklider, J. O. Schorge, R. S. Berkowitz, et al. Haptoglobin-{alpha} Subunit As Potential Serum Biomarker in Ovarian Cancer: Identification and Characterization Using Proteomic Profiling and Mass Spectrometry Clin. Cancer Res., August 1, 2003; 9(8): 2904 - 2911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Bast Jr Status of Tumor Markers in Ovarian Cancer Screening J. Clin. Oncol., May 15, 2003; 21(90100): 200s - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Baker The Central Role of Receiver Operating Characteristic (ROC) Curves in Evaluating Tests for the Early Detection of Cancer J Natl Cancer Inst, April 2, 2003; 95(7): 511 - 515. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Wang, J. Chao, and L. Chao Adenovirus-mediated human prostasin gene delivery is linked to increased aldosterone production and hypertension in rats Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2003; 284(4): R1031 - R1036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Welsh, L. M. Sapinoso, S. G. Kern, D. A. Brown, T. Liu, A. R. Bauskin, R. L. Ward, N. J. Hawkins, D. I. Quinn, P. J. Russell, et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum PNAS, March 18, 2003; 100(6): 3410 - 3415. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. P. Diamandis, A. Scorilas, S. Fracchioli, M. van Gramberen, H. de Bruijn, A. Henrik, A. Soosaipillai, L. Grass, G. M. Yousef, U.-H. Stenman, et al. Human Kallikrein 6 (hK6): A New Potential Serum Biomarker for Diagnosis and Prognosis of Ovarian Carcinoma J. Clin. Oncol., March 15, 2003; 21(6): 1035 - 1043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-Y. Luo, D. Katsaros, A. Scorilas, S. Fracchioli, R. Bellino, M. van Gramberen, H. de Bruijn, A. Henrik, U.-H. Stenman, M. Massobrio, et al. The Serum Concentration of Human Kallikrein 10 Represents a Novel Biomarker for Ovarian Cancer Diagnosis and Prognosis Cancer Res., February 15, 2003; 63(4): 807 - 811. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T. Baron, E. M. Cora, J. M. Lafky, C. H. Boardman, M. C. Buenafe, A. Rademaker, D. Liu, D. A. Fishman, K. C. Podratz, and N. J. Maihle Soluble Epidermal Growth Factor Receptor (sEGFR/sErbB1) as a Potential Risk, Screening, and Diagnostic Serum Biomarker of Epithelial Ovarian Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2003; 12(2): 103 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Young Early-Stage Ovarian Cancer: To Treat or Not To Treat J Natl Cancer Inst, January 15, 2003; 95(2): 94 - 95. [Full Text] [PDF]
|
|
|
|
|
|
P. F. Macgregor and J. A. Squire Application of Microarrays to the Analysis of Gene Expression in Cancer Clin. Chem., August 1, 2002; 48(8): 1170 - 1177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kuramoto, K. Morimura, S. Yamashita, E. Okochi, N. Watanabe, T. Ohta, M. Ohki, S. Fukushima, T. Sugimura, and T. Ushijima Etiology-specific Gene Expression Profiles in Rat Mammary Carcinomas Cancer Res., July 1, 2002; 62(13): 3592 - 3597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. O'Regan, C. Fleming, J. D. Seidman, R. C. Wallach, S. C. Mok, S. J. Skates, R. S. Berkowitz, and D. W. Cramer Osteopontin as a Biomarker for Ovarian Cancer JAMA, June 26, 2002; 287(24): 3208 - 3210. [Full Text] [PDF]
|
|
|
|
|
|
J.-H. Kim, S. J. Skates, T. Uede, K.-k. Wong, J. O. Schorge, C. M. Feltmate, R. S. Berkowitz, D. W. Cramer, and S. C. Mok Osteopontin as a Potential Diagnostic Biomarker for Ovarian Cancer JAMA, April 3, 2002; 287(13): 1671 - 1679. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. B. Mills, R. C. Bast Jr., and S. Srivastava Future for Ovarian Cancer Screening: Novel Markers From Emerging Technologies of Transcriptional Profiling and Proteomics J Natl Cancer Inst, October 3, 2001; 93(19): 1437 - 1439. [Full Text] [PDF]
|
|